James Falcon
Family Medicine · Rio Grande City, TXNPI 1144480815
Payments from drug & device makers
Across 15 payments — averaging $46,730 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$683K
- Genentech, Inc.$18K
- F. Hoffmann-la Roche AG$80
- Lilly USA, LLC$31
- Nevro Corp.$22
- AbbVie$22
- plus $41 from 2 others
Across 5 payments — averaging $2027.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$10K
What the payments were for
- Food & beverage$195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $683,187 |
| Genentech, Inc. | 3 | $17,572 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Lilly USA, LLC | 1 | $31 |
| Nevro Corp. | 1 | $22 |
| AbbVie | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
How this compares
$700,954 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $42,476 |
| OzempicSemaglutide | 39 | $36,105 |
| JanuviaSitagliptin Phosphate | 19 | $29,298 |
| LinzessLinaclotide | 29 | $27,874 |
| FarxigaDapagliflozin Propanediol | 22 | $25,203 |
| TrulicityDulaglutide | 25 | $24,536 |
| TradjentaLinagliptin | 17 | $17,163 |
| MyrbetriqMirabegron | 13 | $9,750 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,223 |
| Levemir FlexpenInsulin Detemir | 11 | $1,672 |
| Metoprolol Succinate | 79 | $1,573 |
| Novolog FlexpenInsulin Aspart | 11 | $1,378 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $1,226 |
| Atorvastatin Calcium | 109 | $1,152 |
| Omeprazole | 52 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $22 | $27,87429 claims |
| Lilly USA, LLCTrulicity | $31 | $24,53625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Rio Grande City
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.